CASTRATION-RESISTANT PROSTATE CARCINOMA
Clinical trials for CASTRATION-RESISTANT PROSTATE CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new CASTRATION-RESISTANT PROSTATE CARCINOMA trials appear
Sign up with your email to follow new studies for CASTRATION-RESISTANT PROSTATE CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Could fewer doses be just as effective for prostate cancer?
Disease control Recruiting nowThis study looks at whether men with advanced prostate cancer that has spread can safely stop treatment after 5 cycles of a targeted radiation drug (177Lu-PSMA-617) instead of the usual 6 cycles. The goal is to see if the shorter plan controls the cancer just as well while reduci…
Matched conditions: CASTRATION-RESISTANT PROSTATE CARCINOMA
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 17, 2026 04:35 UTC
-
Can a second dose of radioactive therapy beat back prostate cancer?
Disease control Recruiting nowThis study tests whether giving a second round of a radioactive drug called 177Lu-PSMA-617 can help men with advanced prostate cancer that stopped responding to hormone therapy and chemotherapy. The drug targets and delivers radiation directly to cancer cells. Only patients who h…
Matched conditions: CASTRATION-RESISTANT PROSTATE CARCINOMA
Phase: PHASE2 • Sponsor: Jonsson Comprehensive Cancer Center • Aim: Disease control
Last updated May 17, 2026 04:35 UTC
-
Engineered immune cells take on Hard-to-Treat prostate cancer
Disease control Recruiting nowThis early-stage trial tests a new treatment for men with a type of advanced prostate cancer that no longer responds to hormone therapy. The treatment uses the patient's own immune cells, which are modified in a lab to better recognize and attack cancer cells. Some participants w…
Matched conditions: CASTRATION-RESISTANT PROSTATE CARCINOMA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 17, 2026 04:34 UTC
-
Could high testosterone boost chemo in tough prostate cancers?
Disease control Recruiting nowThis study tests whether giving high levels of testosterone (much higher than normal) can make chemotherapy or a targeted radiation drug work better in men with advanced prostate cancer that has stopped responding to standard hormone therapy. About 69 participants will receive te…
Matched conditions: CASTRATION-RESISTANT PROSTATE CARCINOMA
Phase: PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated May 17, 2026 04:29 UTC
-
New combo therapy aims to slow Tough-to-Treat prostate cancer
Disease control Recruiting nowThis study tests whether adding carboplatin to the standard chemotherapy cabazitaxel helps men with advanced prostate cancer that no longer responds to hormone therapy. About 528 participants will receive either cabazitaxel alone or cabazitaxel plus carboplatin. The goal is to se…
Matched conditions: CASTRATION-RESISTANT PROSTATE CARCINOMA
Phase: PHASE3 • Sponsor: SWOG Cancer Research Network • Aim: Disease control
Last updated May 17, 2026 04:15 UTC
-
New combo aims to boost radiation's punch against hard-to-treat prostate cancer
Disease control Recruiting nowThis study tests whether giving a drug called abemaciclib before a targeted radiation therapy (177Lu-PSMA-617) can help treat metastatic castration-resistant prostate cancer that has stopped responding to other treatments. Abemaciclib may increase the number of targets (PSMA) on …
Matched conditions: CASTRATION-RESISTANT PROSTATE CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Vadim S Koshkin • Aim: Disease control
Last updated May 15, 2026 11:53 UTC
-
New hope for advanced cancers with DNA repair flaws: PARP inhibitor trial opens
Disease control Recruiting nowThis study tests the drug talazoparib in adults with advanced solid tumors (like breast, prostate, ovarian, pancreatic, or stomach cancer) that have certain gene changes affecting DNA repair. The drug blocks a protein called PARP, which cancer cells need to fix their DNA, potenti…
Matched conditions: CASTRATION-RESISTANT PROSTATE CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 12, 2026 13:43 UTC
-
New hope for Hard-to-Treat prostate cancer: drug combo trial launches
Disease control Recruiting nowThis study tests a combination of two drugs, ruxolitinib and enzalutamide, in men with advanced prostate cancer that has spread and no longer responds to hormone therapy. The goal is to find the safest dose and see if the combo can shrink tumors or lower PSA levels. About 20 part…
Matched conditions: CASTRATION-RESISTANT PROSTATE CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: University of Michigan Rogel Cancer Center • Aim: Disease control
Last updated May 11, 2026 20:49 UTC
-
Testosterone therapy shows promise for Hard-to-Treat prostate cancer
Disease control Recruiting nowThis early-stage study tests a treatment called bipolar androgen therapy for men with advanced prostate cancer that no longer responds to standard hormone therapy and has spread. The approach rapidly switches testosterone levels from very low to very high to shock cancer cells an…
Matched conditions: CASTRATION-RESISTANT PROSTATE CARCINOMA
Phase: PHASE1 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated May 11, 2026 20:39 UTC
-
Engineered immune cells take on Hard-to-Treat prostate cancer
Disease control Recruiting nowThis study tests whether a new cell therapy (STEAP1 CART) combined with the drug enzalutamide is safe and effective for men with advanced prostate cancer that has spread and stopped responding to standard treatments. About 48 participants will receive their own immune cells, modi…
Matched conditions: CASTRATION-RESISTANT PROSTATE CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated May 06, 2026 16:01 UTC
-
New combo aims to make resistant prostate cancer cells visible to targeted radiation
Disease control Recruiting nowThis study tests whether the drug vorinostat can help men with a type of advanced prostate cancer that has low levels of a specific marker (PSMA). The marker is needed for a radioactive therapy called 177Lu-PSMA-617 to work. By giving vorinostat first, the hope is to increase PSM…
Matched conditions: CASTRATION-RESISTANT PROSTATE CARCINOMA
Phase: PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Apr 30, 2026 15:49 UTC
-
Freeze and zap: new combo therapy aims to crush bone cancer pain
Symptom relief Recruiting nowThis study tests whether freezing bone tumors (cryoablation) before giving radiation therapy works better than radiation alone for reducing pain. About 40 adults with cancer that has spread to the bones will be enrolled. The goal is to see if the combination provides more complet…
Matched conditions: CASTRATION-RESISTANT PROSTATE CARCINOMA
Phase: NA • Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated May 13, 2026 15:58 UTC
-
Can DNA glitches predict prostate cancer treatment success?
Knowledge-focused Recruiting nowThis study looks at men with advanced prostate cancer that has spread to the bones. Researchers want to see if certain DNA repair problems in the cancer affect how well the drug radium-223 works. The goal is to help doctors choose better treatments in the future. About 48 men wil…
Matched conditions: CASTRATION-RESISTANT PROSTATE CARCINOMA
Sponsor: University of Washington • Aim: Knowledge-focused
Last updated May 17, 2026 04:35 UTC
-
DNA-Guided prostate cancer therapy put to the test
Knowledge-focused Recruiting nowThis study is for men with advanced prostate cancer that no longer responds to hormone therapy. Researchers want to see if using genetic tests on tumor tissue can help pick the most effective treatment from several options, including newer targeted drugs and chemotherapy. About 4…
Matched conditions: CASTRATION-RESISTANT PROSTATE CARCINOMA
Phase: PHASE2 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Knowledge-focused
Last updated May 15, 2026 11:57 UTC
-
Biopsies reveal secrets of prostate cancer resistance
Knowledge-focused Recruiting nowThis study looks at why some advanced prostate cancers become resistant to a treatment called 177Lu-PSMA. Researchers will take small tissue samples (biopsies) from tumors during treatment to find genetic changes that cause resistance. The goal is to learn how to make treatments …
Matched conditions: CASTRATION-RESISTANT PROSTATE CARCINOMA
Phase: PHASE1 • Sponsor: Jonsson Comprehensive Cancer Center • Aim: Knowledge-focused
Last updated May 11, 2026 20:53 UTC